Following injection, the peptides demonstrate: Subcutaneous absorption with median time to maximum concentration (tmax) of 12-24 hours for GLP1 and 24-72 hours for cagrilintide High albumin binding for both peptides (approximately 99% for GLP1), providing protection from enzymatic degradation No pharmacokinetic interaction with co-administration not affecting exposure or elimination of either peptide Steady-state achievement occurring after 4-5 weeks of once-weekly dosing for both components Predictable dose-proportional exposure with area under the curve increasing proportionally with dose Phase 1b studies confirmed that cagrilintide doses from 0.16 to 4.5 mg produced area under the curve values ranging from 926 to 24,271 nmol times h/L, while GLP1 2.4 mg consistently produced values of 12,757 to 15,305 nmol times h/L regardless of cagrilintide co-administration dose
- Consultation is FREE of charge - VAT is included and TAX FREE for travelers
Elsevier, Amsterdam, pp 326362 Maselli J, Hales BF, Chan P, Robaire B (2012) Exposure to bleomycin, etoposide, and cis-platinum alters rat sperm chromatin integrity and sperm head protein profile1
10.1016/j.phymed.2024.155636 99 DavisA
